Human Immunodeficiency Virus: A Global Health Issue

Introduction
Human Immunodeficiency Virus (HIV) is a major global health issue that affects millions of people worldwide. Discovered in the early 1980s, HIV attacks the body's immune system, particularly the CD4 cells (T cells), which are crucial for fighting infections. Without treatment, HIV can progress to Acquired Immunodeficiency Syndrome (AIDS), a condition where the immune system is severely compromised. Despite significant advancements in treatment and prevention, HIV remains a critical public health concern.

History of HIV

AIDS (Acquired Immunodeficiency Syndrome) was first identified in the early 1980s, AIDS rapidly became a global health crisis. The initial cases were reported among gay men in the U.S., leading to stigma and slow responses. In 1983, scientists identified HIV as the virus responsible for AIDS.

HIV attacks the immune system, leading to severe infections and cancers. The epidemic spread globally, particularly affecting sub-Saharan Africa. By the mid-1990s, AIDS was a leading cause of death worldwide.

The introduction of antiretroviral therapy (ART) in 1996 marked a turning point, transforming AIDS from a fatal disease into a manageable condition. Despite advancements, stigma, and access to treatment remain challenges, especially in low-income regions.

By 2020, over 38 million people were living with HIV, and efforts to end the epidemic continue through education, prevention, and treatment programs.

Transmission and Epidemiology

HIV is primarily transmitted through contact with certain body fluids from an infected person, including blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common modes of transmission are unprotected sexual contact, sharing needles or syringes, and from mother to child during childbirth or breastfeeding.

Globally, around 38 million people were living with HIV in 2019, according to the World Health Organization (WHO). Sub-Saharan Africa remains the hardest-hit region, accounting for a significant proportion of new infections and deaths. However, HIV affects people in every part of the world, with different regions facing unique challenges.

Symptoms and Progression

HIV progresses in stages, with the initial stage often characterized by flu-like symptoms, such as fever, sore throat, and fatigue. This acute phase typically occurs within 2-4 weeks after exposure and is known as primary or acute HIV infection. Following this, the virus enters a chronic or clinical latency stage, during which it continues to multiply at low levels but may not cause noticeable symptoms. Without treatment, HIV eventually progresses to AIDS, the most severe stage of the infection. At this point, the immune system is so damaged that the body becomes vulnerable to opportunistic infections and certain cancers. Without proper treatment, people with AIDS typically survive about three years.

Antiretroviral Therapy (ART)

The development of antiretroviral therapy (ART) in the mid-1990s revolutionized HIV treatment. ART involves a combination of medications that work together to suppress the virus, allowing the immune system to recover and function effectively. When taken consistently and correctly, ART can reduce the viral load in the blood to undetectable levels.

This not only helps people with HIV live longer, healthier lives but also reduces the risk of transmitting the virus to others, a concept known as "undetectable equals untransmittable" (U=U).

Despite the effectiveness of ART, challenges remain. Access to treatment is uneven, particularly in low- and middle-income countries. In some areas, people face barriers such as stigma, discrimination, and limited healthcare infrastructure, which can prevent them from accessing the care they need.

HIV Prevention

Preventing HIV transmission is a key focus of global health efforts. A variety of prevention strategies have been developed, including:

1.    Condom Use: Consistent and correct use of condoms during sexual activity is highly effective in preventing HIV transmission.

2.    Pre-exposure Prophylaxis (PrEP): PrEP is a daily medication that people at high risk of HIV can take to reduce their chances of becoming infected. When taken as prescribed, PrEP is highly effective.

3.     Post-exposure Prophylaxis (PEP): PEP involves taking antiretroviral medicines after potential exposure to HIV to prevent infection. It must be started within 72 hours of exposure and taken for 28 days.

4.     Harm Reduction: For people who inject drugs, harm reduction strategies, such as needle exchange programs and opioid substitution therapy, can significantly reduce the risk of HIV transmission.

5.     Mother-to-Child Transmission Prevention: Pregnant women with HIV can take ART to reduce the risk of transmitting the virus to their babies during childbirth and breastfeeding.

Despite these advances, prevention efforts are often hindered by social, cultural, and economic factors. In some regions, condoms and PrEP are not widely available, and there may be resistance to their use due to cultural or religious beliefs. Harm reduction programs may face legal and political barriers, further complicating efforts to prevent HIV transmission.

Stigma and Discrimination

One of the most significant challenges in addressing HIV is the stigma and discrimination that surround the disease. People living with HIV often face social isolation, discrimination in employment and healthcare, and even violence. Stigma can discourage people from getting tested, seeking treatment, and disclosing their status to others, which can further fuel the epidemic.

Combatting stigma requires education, awareness, and legal protections for people living with HIV. Public health campaigns that promote understanding and acceptance of people with HIV are crucial, as are laws that protect their rights and prevent discrimination.

HIV Testing

HIV testing is a critical component of both prevention and treatment efforts. Early diagnosis allows individuals to start ART before their immune system is significantly compromised, improving health outcomes and reducing the risk of transmission to others. Rapid tests that provide results in minutes and home-based testing kits have made testing more accessible, but barriers remain, particularly in areas with limited healthcare infrastructure.

Co-infections and HIV

People living with HIV are at higher risk of co-infections, particularly tuberculosis (TB), hepatitis B and C, and other sexually transmitted infections (STIs). TB is the leading cause of death among people with HIV, highlighting the importance of integrated care that addresses both HIV and co-infections. Preventive measures, such as vaccines for hepatitis B, and routine screening for co-infections are essential in managing the health of people living with HIV.

The Future of HIV Research and Treatment

While there is no cure for HIV, ongoing research is focused on finding one, as well as improving existing treatments and prevention methods. Researchers are exploring various strategies, including gene therapy, immune modulation, and therapeutic vaccines, which aim to control or eradicate the virus.

The search for an HIV vaccine remains a top priority. Although several vaccine candidates have shown promise in early trials, an effective vaccine that can prevent HIV infection has yet to be developed. Continued investment in research is crucial to achieving long-term solutions to the HIV epidemic.

Conclusion

HIV remains a significant global health challenge, but the progress made in treatment and prevention over the past few decades is remarkable. Antiretroviral therapy has transformed HIV from a fatal disease to a manageable chronic condition, and a range of prevention strategies has been developed to reduce the risk of transmission. However, challenges such as stigma, discrimination, and unequal access to care persist, requiring ongoing efforts from governments, healthcare providers, and communities.

Ending the HIV epidemic will require a combination of scientific innovation, social change, and global solidarity. By addressing the social and structural factors that contribute to HIV vulnerability and ensuring that everyone has access to the tools and services they need, the vision of an AIDS-free generation may one day become a reality.

 
SMM Musabbir Uddin is a student of
 Universal Medical College, Dhaka.